What the FDA labels say about taking them together
Infliximab and tocilizumab
Infliximab's FDA label of August 28, 2026 names tocilizumab in its drug interactions section; the tocilizumab labels PlainMeds reads (4) do not name infliximab. The infliximab label: “The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including AVSOLA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection.”
Check it at the source: the infliximab FDA label on DailyMed (effective August 28, 2026); the tocilizumab FDA label on DailyMed (effective December 16, 2025, Genentech, Inc.).
What does the infliximab label say about tocilizumab?
Infliximab label, drug interactionsThe concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including RENFLEXIS, should be avoided because of the possibility of increased immunosuppression and increased risk of infection.
Source: FDA drug label (Inflectra, BLA125544), Pfizer Laboratories Div Pfizer Inc, effective July 28, 2026 (SPL set 37eaca10-d812-48bc-8b8e-b836bfa9968f), via openFDA
Source: FDA drug label (Avsola, BLA761086), Amgen, Inc, effective July 22, 2026 (SPL set de34bcb7-b524-45c8-9181-61c6f48d540e), via openFDA
Source: FDA drug label (Infliximab, BLA103772), Janssen Biotech, Inc., effective February 11, 2026 (SPL set b05c174f-832c-4321-b34f-2c4ad3742269), via openFDA
Source: FDA drug label (Renflexis), Organon LLC, effective August 28, 2026 (SPL set dbf738c4-3fac-4422-a9d8-51d9c83a8789), via openFDA; the full label on DailyMed
What does the tocilizumab label say about infliximab?
Tocilizumab's label (effective December 16, 2025) and its 3 other brand-application labels do not name infliximab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ACTEMRA), Genentech, Inc., effective December 16, 2025 (SPL set 2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Infliximab | Tocilizumab | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis | Rheumatoid arthritis, COVID-19 |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $821.00 per mL 162 mg/0.9 mL autoinjct |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once